Scarica l'app Stockscreener
2.03
22.29%
0.37
Pre-mercato:
2.01
-0.02
-0.99%
Precedente Chiudi:
$1.66
Aprire:
$1.65
Volume 24 ore:
890.11K
Relative Volume:
4.75
Capitalizzazione di mercato:
$32.63M
Reddito:
-
Utile/perdita netta:
$-8.29M
Rapporto P/E:
-2.90
EPS:
-0.7
Flusso di cassa netto:
$-6.47M
1 W Prestazione:
+26.09%
1M Prestazione:
+47.10%
6M Prestazione:
+56.15%
1 anno Prestazione:
+42.96%
Intervallo 1D:
$1.65
$2.065
Intervallo di 1 settimana:
$1.51
$2.065
Portata 52W:
$0.94
$2.065
NanoViricides Inc Stock (NNVC) Company Profile
Nome
NanoViricides Inc
Settore
Industria
Telefono
203-937-6137
Indirizzo
1 Controls Drive, Shelton, CT
Confronta NNVC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
2.03 | 28.94M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2015-02-11 | Iniziato | Midtown Partners | Strong Buy |
NanoViricides Inc Borsa (NNVC) Ultime notizie
How to build a dashboard for NanoViricides Inc. stockEarnings Performance Report & Risk Controlled Swing Alerts - newser.com
How NanoViricides Inc. stock trades after earningsDollar Strength & Low Risk Investment Opportunities - newser.com
Is NanoViricides Inc. stock undervalued vs historical averagesPortfolio Return Report & Verified High Yield Trade Plans - newser.com
Is NanoViricides Inc. stock a defensive play amid uncertainty2025 Analyst Calls & Reliable Volume Spike Alerts - newser.com
How to use Fibonacci retracement on NanoViricides Inc.2025 Bull vs Bear & Daily Entry Point Trade Alerts - newser.com
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - Norwich Bulletin
NanoViricides to Present Antiviral Drug Pipeline at Spartan Capital Investor Conference - citybuzz -
Why NanoViricides Inc. stock appeals to dividend seekersJobs Report & High Accuracy Swing Entry Alerts - newser.com
Why NanoViricides Inc. stock is upgraded to buy2025 Trade Ideas & Smart Swing Trading Techniques - newser.com
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd - ACCESS Newswire
Can NanoViricides Inc. (NV3P) stock ride next bull market cycleMarket Risk Report & Consistent Income Trade Recommendations - newser.com
Can NanoViricides Inc. stock hit consensus price targetsMarket Movement Recap & Consistent Profit Trading Strategies - newser.com
NanoViricides to present at Spartan Capital Investor Conference 2025 in New York - Proactive financial news
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides - Palm Beach Daily News
How NanoViricides Inc. (NV3P) stock trades after rate cutsJuly 2025 PreEarnings & Growth-Oriented Investment Plans - newser.com
Combining machine learning predictions for NanoViricides Inc.Trade Volume Summary & AI Powered Buy and Sell Recommendations - newser.com
Will NanoViricides Inc. stock split attract more investorsIPO Watch & Accurate Technical Buy Alerts - newser.com
What MACD trends signal for NanoViricides Inc. stock2025 Top Gainers & Fast Gain Stock Tips - newser.com
Has NanoViricides Inc. found a price floorTrade Performance Summary & Detailed Earnings Play Alerts - newser.com
Using portfolio simulators with NanoViricides Inc. includedInflation Watch & Technical Pattern Alert System - newser.com
NanoViricides, Inc. Has Filed its Annual Report - The Marion Star
NanoViricides Dual Track Clinical Strategy Explained by a Research ReportBroad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses - The Holland Sentinel
NanoViricides targets broad-spectrum virus threats – ICYMI - Proactive financial news
Identifying reversal signals in NanoViricides Inc.2025 Volume Leaders & Long-Term Growth Stock Strategies - newser.com
Detecting support and resistance levels for NanoViricides Inc.Weekly Trade Report & Community Verified Trade Alerts - newser.com
NanoViricides Inc Azioni (NNVC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):